Corbus Pharmaceuticals Holding (CRBP) - Net Assets
Based on the latest financial reports, Corbus Pharmaceuticals Holding (CRBP) has net assets worth $92.15 Million USD as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($109.51 Million) and total liabilities ($17.37 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check CRBP financial resilience to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $92.15 Million |
| % of Total Assets | 84.14% |
| Annual Growth Rate | N/A |
| 5-Year Change | 214.58% |
| 10-Year Change | 1485.17% |
| Growth Volatility | 264.08 |
Corbus Pharmaceuticals Holding - Net Assets Trend (2012–2024)
This chart illustrates how Corbus Pharmaceuticals Holding's net assets have evolved over time, based on quarterly financial data. Also explore CRBP current and non-current assets for the complete picture of this company's asset base.
Annual Net Assets for Corbus Pharmaceuticals Holding (2012–2024)
The table below shows the annual net assets of Corbus Pharmaceuticals Holding from 2012 to 2024. For live valuation and market cap data, see market value of Corbus Pharmaceuticals Holding.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $142.43 Million | +2162.68% |
| 2023-12-31 | $-6.91 Million | -120.93% |
| 2022-12-31 | $32.99 Million | -52.26% |
| 2021-12-31 | $69.11 Million | +52.64% |
| 2020-12-31 | $45.27 Million | +635.27% |
| 2019-12-31 | $6.16 Million | -77.63% |
| 2018-12-31 | $27.52 Million | -52.37% |
| 2017-12-31 | $57.78 Million | +547.85% |
| 2016-12-31 | $8.92 Million | -0.73% |
| 2015-12-31 | $8.99 Million | +53.26% |
| 2014-12-31 | $5.86 Million | +428.78% |
| 2013-12-31 | $-1.78 Million | -898779.93% |
| 2012-12-31 | $-198.38 | -- |
Equity Component Analysis
This analysis shows how different components contribute to Corbus Pharmaceuticals Holding's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 47689171576.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $1.00K | 0.00% |
| Other Comprehensive Income | $35.00K | 0.02% |
| Other Components | $619.28 Million | 434.81% |
| Total Equity | $142.43 Million | 100.00% |
Corbus Pharmaceuticals Holding Competitors by Market Cap
The table below lists competitors of Corbus Pharmaceuticals Holding ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Manulife Holdings Bhd
KLSE:1058
|
$133.76 Million |
|
Atlas Lithium Corporation Common Stock
NASDAQ:ATLX
|
$133.83 Million |
|
Kolibri Global Energy Inc. Common stock
NASDAQ:KGEI
|
$133.99 Million |
|
ENDOMINES FINLAND OYJ EO1
F:H13
|
$134.05 Million |
|
B’IN Live Co Ltd
TW:6625
|
$133.70 Million |
|
Champion Microelectronic Corp
TW:3257
|
$133.61 Million |
|
Hua Jung Components Co Ltd
TWO:5328
|
$133.58 Million |
|
Texmaco Infrastructure & Holdings Limited
NSE:TEXINFRA
|
$133.55 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Corbus Pharmaceuticals Holding's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from -6,905,000 to 142,428,000, a change of 149,333,000.
- Net loss of 40,209,000 reduced equity.
- New share issuances of 182,058,000 increased equity.
- Other comprehensive income increased equity by 36,000.
- Other factors increased equity by 7,448,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-40.21 Million | -28.23% |
| Share Issuances | $182.06 Million | +127.82% |
| Other Comprehensive Income | $36.00K | +0.03% |
| Other Changes | $7.45 Million | +5.23% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Corbus Pharmaceuticals Holding's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.79x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2012-12-31 | $-0.85 | $10.30 | x |
| 2013-12-31 | $-2.07 | $10.30 | x |
| 2014-12-31 | $8.72 | $10.30 | x |
| 2015-12-31 | $8.60 | $10.30 | x |
| 2016-12-31 | $6.50 | $10.30 | x |
| 2017-12-31 | $34.55 | $10.30 | x |
| 2018-12-31 | $14.49 | $10.30 | x |
| 2019-12-31 | $2.89 | $10.30 | x |
| 2020-12-31 | $17.38 | $10.30 | x |
| 2021-12-31 | $16.86 | $10.30 | x |
| 2022-12-31 | $7.91 | $10.30 | x |
| 2023-12-31 | $-1.60 | $10.30 | x |
| 2024-12-31 | $13.05 | $10.30 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Corbus Pharmaceuticals Holding utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -28.23%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.09x
- Recent ROE (-28.23%) is above the historical average (-176.46%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | 0.00% | 0.00% | 0.00x | 0.00x | $-867.12 |
| 2013 | 0.00% | 0.00% | 0.00x | 0.00x | $-424.03K |
| 2014 | -43.33% | 0.00% | 0.00x | 1.13x | $-3.13 Million |
| 2015 | -98.51% | -1365.05% | 0.05x | 1.43x | $-9.75 Million |
| 2016 | -224.22% | -1046.27% | 0.11x | 2.01x | $-20.89 Million |
| 2017 | -56.11% | -1328.65% | 0.04x | 1.16x | $-38.20 Million |
| 2018 | -202.27% | -1154.48% | 0.10x | 1.71x | $-58.42 Million |
| 2019 | -1160.42% | -197.69% | 0.74x | 7.98x | $-72.07 Million |
| 2020 | -245.76% | -2826.08% | 0.04x | 2.26x | $-115.80 Million |
| 2021 | -65.92% | -5166.42% | 0.01x | 1.56x | $-52.46 Million |
| 2022 | -169.24% | 0.00% | 0.00x | 2.01x | $-59.13 Million |
| 2023 | 0.00% | 0.00% | 0.00x | 0.00x | $-43.91 Million |
| 2024 | -28.23% | 0.00% | 0.00x | 1.09x | $-54.45 Million |
Industry Comparison
This section compares Corbus Pharmaceuticals Holding's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $44,828,400
- Average return on equity (ROE) among peers: -124.18%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Corbus Pharmaceuticals Holding (CRBP) | $92.15 Million | 0.00% | 0.19x | $133.75 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $118.88 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $3.60 Million | -91.89% | 0.28x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $171.87 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $448.19K |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $88.00 Million | -44.09% | 0.34x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $80.00K | -31.70% | 0.38x | $26.41 Million |
| Abivax SA American Depositary Shares (ABVX) | $40.58 Million | -434.26% | 4.06x | $9.33 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $23.36 Million | -97.44% | 0.37x | $3.74 Billion |
About Corbus Pharmaceuticals Holding
Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation o… Read more